| Home Market Dynamics You and Market Sector Analysis Company Insights AI Investing About Contact Us Login |
| The price action of Health Care (XLV) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The overall sentiment for Health Care sector is very positive (overall 2, positive 2.8, negative -0.8) on 20251105. The forces of Price Level (2), Sentiment towards Fundamentals (1.9), Option Speculation (1.5), Sector Price Trend (0.1), and Broad Market Trend (-0.6) will drive up the price. The forces of Valuation Sentiment (-1), and Market Risk Prefrence (0) will drive down the price. 'Buy the dips' is the preferred trading strategy. Hourly SMA 20 trend line is likely to provide a support from any pullbacks. The swing to upside will be significant considering the high positive sentiment forces (2.8). The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on XLV trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. |
| Date | Attention | Average Attention | Price | Price Level | Change | SMA10 Trend | Market Sentiment | Trend Sentiment | Fundamentals | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-05 | 2% | 2% | 145.64 | 74 | 0.43% | 0% | 0.7 | 0.1 | 1.9 | 1.2 |
| 2025-11-04 | 3% | 1.9% | 145.01 | 65 | 0.42% | 0% | 0.6 | -0.1 | 1.9 | 4.4 |
| 2025-11-03 | 2% | 1.7% | 144.41 | 54 | 0.12% | 0% | 0.3 | -0.5 | 1.7 | 2.7 |
| 2025-11-02 | 1% | 1.6% | 1.2 | -0.3 | 1.8 | 0 | ||||
| 2025-11-01 | 1% | 1.6% | 1.1 | -0.3 | 1.7 | 1.5 | ||||
| 2025-10-31 | 2% | 1.4% | 144.23 | 51 | -0.05% | 0.07% | 1.1 | -0.3 | 1.7 | 3.5 |
| 2025-10-30 | 3% | 1.3% | 144.3 | 52 | 0.17% | 0.14% | 1.1 | -0.4 | 2 | 4.9 |
| 2025-10-29 | 1% | 1% | 144.05 | 47 | -0.95% | 0.07% | 1.7 | -0.4 | 2.1 | -0.9 |
| 2025-10-28 | 2% | 1% | 145.44 | 74 | -0.65% | 0.21% | 1.8 | 0.2 | 2 | 5.2 |
| 2025-10-27 | 1% | 1% | 146.38 | 87 | 0.23% | 0.35% | 1.5 | 0.3 | 1.9 | 2.9 |
| Both emotion scores and sentiment scores are calculated in a -10 - +10 scale. | The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| 1 (-6) Novo Nordisk Is Seeing Slowing Demand for GLP-1s Wegovy and Ozempic Novo Nordisk cuts its outlook as it sees slowing demand for its GLP-1 weight loss and diabetes treatments. (https://www.investopedia.com/) Wed. Nov 5, 2025 | |
| 2 (8) Jazz Pharmaceuticals Plc Reveals Advance In Q3 Bottom Line Jazz Pharmaceuticals plc (JAZZ) reported earnings for its third quarter that Increases, from the same period last year The company's bottom line totaled $251. (https://www.rttnews.com/) Wed. Nov 5, 2025 | |
| 3 (-5) Pfizer Loses Legal Bid to Temporarily Block Novo’s Metsera Offer A judge denied Pfizer Inc.’s request to temporarily block Novo Nordisk A/S’ $10 billion bid to acquire the obesity startup Metsera Inc., saying the US pharmaceutical company’s objections to the deal don’t warrant a delay. (https://www.bloomberg.com/) Wed. Nov 5, 2025 | |
| 4 (2) Apple's reported Google deal, Teva & Axon post-earnings moves Market Domination host Josh Lipton examines some of Wednesday's trending tickers. Apple (AAPL) is reportedly nearing a deal with Alphabet (GOOG, GOOGL) to overhaul Siri, according to Bloomberg. Teva (TEVA) stock rose after the company reported earnings, while Axon (AXON) stock fell after the company's quarterly results missed estimates. To watch more expert insights and analysis on the latest market action, check out more Market Domination. (https://finance.yahoo.com/) Wed. Nov 5, 2025 | |
| 5 (2) GLP-1 goliath updates demand for top weight loss drug A weight-loss giant reports Q3 earnings, causing a stock swing. (https://www.thestreet.com/) Wed. Nov 5, 2025 | |
| 6 (-5) FTC Staff Raise Questions About Novo Bid for Metsera Staff members at the US Federal Trade Commission said it appears Novo Nordisk A/S’ proposed bid for Metsera Inc. “may violate the procedural provisions” of the law that requires a premerger review. (https://www.bloomberg.com/) Wed. Nov 5, 2025 | |
| 7 (8) Tempus AI Growth Outlook Boosted By Higher ASPs, Pharma Contracts, Analyst Says Tempus AI beats Q3 revenue estimates with $334.21M, narrows adjusted loss to $0.11 per share, and raises FY25 guidance to $1.265B. (https://www.benzinga.com/) Wed. Nov 5, 2025 | |
| 8 (0) 10 Health Care Stocks Whale Activity In Today's Session (https://www.benzinga.com/) Wed. Nov 5, 2025 | |
| 9 (-6) Novo Nordisk downgrades sales outlook again amid bidding war with Pfizer for Metsera Management lowers full-year guidance, warns about competition, launches bid for Metsera. (https://www.marketwatch.com/) Wed. Nov 5, 2025 | |
| 10 (8) Elanco Shares Poised For Upside After Another Quarter Of Outperformance Elanco posts strong Q3 results with 10% sales growth, surpasses forecasts, and raises full-year revenue and earnings guidance for 2025. (https://www.benzinga.com/) Wed. Nov 5, 2025 | |
| 11 (2) Humana Q3 Premium Growth Offsets Membership Drop, Stock Tumbles Humana beat Q3 estimates with $3.24 EPS and $32.65 billion sales, reaffirming 2025 earnings guidance at $17 per share despite Medicare declines. (https://www.benzinga.com/) Wed. Nov 5, 2025 | |
| 12 (-7) Novo Nordisk cuts outlook, IBM layoffs, Pinterest stock plummets Yahoo Finance Senior Reporter Allie Canal takes a closer look at some of Wednesday's trending tickers, including Novo Nordisk (NVO), IBM (IBM), and Pinterest (PINS). To watch more expert insights and analysis on the latest market action, check out more Morning Brief. (https://finance.yahoo.com/) Wed. Nov 5, 2025 | |
| 13 (5) Rivian tops Q3 estimates, Humana stock sinks on high medical costs Yahoo Finance Senior Reporter Allie Canal takes a look at some of Wednesday's trending tickers and stories. Rivian (RIVN) beat on third quarter earnings results. Humana (HUM) stock is under pressure after the company warned that medical costs are higher than usual. Unity Software (U) stock is surging after the company released third quarter results that beat expectations. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts. (https://finance.yahoo.com/) Wed. Nov 5, 2025 | |
| 14 (7) Humana Reports $195 Million Profit As Costs Land Within Expectations Humana reported $195 million in third quarter profits as the health insurer’s medical cost trends were in line with forecasts for the provider of Medicare Advantage. (https://www.forbes.com/) Wed. Nov 5, 2025 | |
| 15 (8) Humana beats quarterly profit estimates on higher premiums, in-line medical costs () -Humana reported third-quarter profit that beat Wall Street estimates on Wednesday, helped by higher premiums and medical costs which were in line with the health insurer's expectations. The company is one of the largest providers of Medicare Advantage plans, under which the U. (https://finance.yahoo.com/) Wed. Nov 5, 2025 | |
| 16 (-7) Humana’s stock falls as Medicaid, health-benefit costs are still problems Medicaid-membership growth outlook was slashed, and as medical costs are still a problem. (https://www.marketwatch.com/) Wed. Nov 5, 2025 | |
| 17 (7) CSL Predicts US Flu-Shot Rebound as Seqirus Expands in Europe CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. (https://www.bloomberg.com/) Wed. Nov 5, 2025 | |
| 18 (8) Obesity drugs may be sold at just $149 a month, get covered under Medicare under a reported White House deal in the works The White House is close to announcing a deal with drugmakers Eli Lilly and Novo Nordisk that would cut the price of obesity drugs to $149 per month in some cases and extend coverage to certain Medicare and Medicaid beneficiaries, according to media reports Tuesday. (https://www.marketwatch.com/) Tue. Nov 4, 2025 | |
| 19 (6) These Stocks Could Be Catalysts for CURE Glossed-over corners of the market have a way of rebounding before many investors notice, indicating risk-tolerant traders may want to remain mindful of the Direxion Daily Healthcare Bull 3X ETF (CURE). (https://www.etftrends.com/) Tue. Nov 4, 2025 | |
| 20 (7) Masimo Corporation Bottom Line Rises In Q3 Masimo Corporation (MASI) announced a profit for its third quarter that Increases, from the same period last year The company's earnings came in at $53.7 million, or $0. (https://www.rttnews.com/) Tue. Nov 4, 2025 | |
| 21 (8) Amgen Lifts Outlook Again After Drug Sales Beat Expectations Amgen Inc. raised its full-year guidance after third-quarter results beat expectations, a positive sign in light of hurdles from Washington and the risks of increased competition. (https://www.bloomberg.com/) Tue. Nov 4, 2025 | |
| 22 (7) Wall Street gets another reason to like Eli Lilly stock, and DuPont's spin is going to plan Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading. (https://www.cnbc.com/) Tue. Nov 4, 2025 | |
| 23 (-6) Analysts Lower Cigna Targets As PBM Segment Guidance Surprises Market Cigna expects 2026–2027 margin pressure from its new rebate-free PBM model as major clients renew at lower margins, prompting analyst target cuts. (https://www.benzinga.com/) Tue. Nov 4, 2025 | |
| 24 (5) Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb Novo Nordisk boosts its Metsera bid to $62.20 per share, valuing the company at $10 billion and outbidding Pfizer in the escalating takeover fight. (https://www.benzinga.com/) Tue. Nov 4, 2025 | |
| 25 (6) Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House Eli Lilly and Company (NYSE:LLY) shares are trading slightly lower on Tuesday after its previous gains following reports indicating the company is close to finalizing a White House agreement to provide its lowest-dose obesity medications at $149 per month, which could open the door to Medicare coverage and broader reimbursement options. (https://www.benzinga.com/) Tue. Nov 4, 2025 | |
| 26 (-6) Pfizer is losing its fight with Novo Nordisk to get back in the obesity-drug game Pfizer’s buyout bid for Metsera was deemed inferior to the latest bid from Novo Nordisk, putting the original agreement in doubt despite legal efforts to enforce it. (https://www.marketwatch.com/) Tue. Nov 4, 2025 | |
| 27 (-5) Pfizer plays hardball in weight-loss drug fight Pfizer has filed two lawsuits to block Novo Nordisk’s $9bn bid to buy Metsera (https://www.ft.com/) Tue. Nov 4, 2025 | |
| 28 (8) Lilly and Novo Rise on Report of Deal for Medicare Coverage Shares of Eli Lilly & Co and Novo Nordisk A/S rose on a report that the companies were preparing to announce new deals with the White House to lower prices for weight-loss drugs in exchange for coverage under Medicare. (https://www.bloomberg.com/) Tue. Nov 4, 2025 | |
| 29 (5) Metsera says Novo Nordisk’s new up to $10 billion bid for obesity drugmaker is ‘superior’ to revised Pfizer offer The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies like Pfizer race to break in. (https://www.cnbc.com/) Tue. Nov 4, 2025 | |
| 30 (7) HIMS CEO Says 'A Little Bit of Craziness' Is The Secret To Building A Global Health Platform Hims & Hers Health (HIMS) CEO Andrew Dudum, sees potential for emotional and medical transformation and plans for global expansion. (https://www.benzinga.com/) Tue. Nov 4, 2025 | |
| 31 (5) Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera. Metsera said Tuesday that Novo is now offering to pay as much as $10 billion for Metsera. Metsera said Pfizer also has changed an offer it made in September of nearly $4.9 billion it to provide more cash up front. (https://finance.yahoo.com/) Tue. Nov 4, 2025 | |
| 32 (5) Pfizer’s revenue falls as COVID sales and vaccine recommendations continue to fade Pfizer’s stock rises as quarterly profit beat profit expectations and the full-year outlook was raised. (https://www.marketwatch.com/) Tue. Nov 4, 2025 | |
| 33 (6) Pfizer Boosts Profit View as It Battles for Obesity Startup Pfizer Inc. raised its 2025 profit forecast for the second time this year, as ongoing cost cuts helped make up for slow sales growth that’s driving its battle for the obesity start up Metsera Inc. (https://www.bloomberg.com/) Tue. Nov 4, 2025 | |
| 34 (7) Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November (https://www.benzinga.com/) Tue. Nov 4, 2025 | |
| 35 (7) Philips Navigates Tariffs Through Cost Discipline, Reaffirms Outlook Philips Q3 earnings topped forecasts as sales rose 3% and margins improved, supported by cost savings and steady North American demand. (https://www.benzinga.com/) Tue. Nov 4, 2025 | |
| 36 (5) Is Eli Lilly a Millionaire Maker? Eli Lilly has a leading position in a hot new drug category, but there's one notable problem to consider. (https://www.fool.com/) Tue. Nov 4, 2025 | |
| 37 (2) Earnings from Uber, Shopify, Spotify and Pfizer: Market Movers Uber (UBER) posted its strongest quarterly growth since late 2023 as customers ordered more rides and deliveries than expected. However, its share price fell in the premarket as its forecasts underwhelmed investors. Meanwhile Spotify's (SPOT) share price rose before the opening bell after the world's largest streaming service reported stronger-than-expected third-quarter results. Other results this morning include Shopify (SHOP) and pharmaceutical giant, Pfizer (PFE). For more live coverage of the markets, watch the full episode of Market Sunrise and visit Yahoo Finance. (https://finance.yahoo.com/) Tue. Nov 4, 2025 | |
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA